Lynx1 Capital Management LP Design Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $270 Million
- Q1 2025
A detailed history of Lynx1 Capital Management LP transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 65,954 shares of DSGN stock, worth $221,605. This represents 0.09% of its overall portfolio holdings.
Number of Shares
65,954Holding current value
$221,605% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding DSGN
# of Institutions
101Shares Held
33.3MCall Options Held
4KPut Options Held
3.1K-
Sr One Capital Management, LP6.53MShares$21.9 Million11.4% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$14.2 Million3.17% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$7.74 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$6.56 Million0.47% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.82MShares$6.11 Million0.02% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $188M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...